Regulatory

Trump Admin Reclassifies State-Licensed Marijuana

President Trump’s acting attorney general ordered the immediate reclassification of FDA-approved and state-licensed marijuana as a less dangerous drug Thursday. The move will make it easier to study medicinal applications of marijuana and could shore up support from influencers who support the research. Acting Attorney General Todd Blanche wrote in a Thursday post that on […]

Trump Admin Reclassifies State-Licensed Marijuana Read More »

Medicare Delays Full Obesity-Drug Program Rollout After Insurers Push Back

The Medicare agency will extend a short-term program that will pay for weight-loss drugs such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, guaranteeing access to the popular medications will continue for seniors next year. The decision by the Centers for Medicare and Medicaid Services comes after big Medicare insurers signaled that they didn’t initially

Medicare Delays Full Obesity-Drug Program Rollout After Insurers Push Back Read More »

House Hearing Highlights ‘Systemic Failure’ at Heart of Hospice, Home Health Fraud

At a lengthy House Committee on Ways & Means hearing Tuesday, hospice and healthcare stakeholders testified about the harm caused by pervasive hospice and home health fraud in California and other states and laid out concrete ways to address the crisis. “Fraud exposes beneficiaries to exploitation and denies them access to appropriate care and undermines

House Hearing Highlights ‘Systemic Failure’ at Heart of Hospice, Home Health Fraud Read More »

No Surprises Act Arbitration Databook

The No Surprises Act (NSA) established a final-offer arbitration process called independent dispute resolution (IDR) to settle payment disputes between health insurers and health care providers for certain out-of-network services. This webpage provides data on how the IDR process is working, including estimates of the average prices emerging from IDR, qualifying payment amounts (QPAs) calculated

No Surprises Act Arbitration Databook Read More »

CMS Proposes Nationwide Mandatory Bundled Payment Model for Joint Replacements

On April 14, the Centers for Medicare & Medicaid Services (CMS) published a proposed rule as part of the Fiscal Year 2027 Hospital Inpatient Prospective Payment System (IPPS) rulemaking that would establish the Comprehensive Care for Joint Replacement Expanded (CJR-X) Model, a mandatory alternative payment model for lower extremity joint replacement (LEJR) procedures that would

CMS Proposes Nationwide Mandatory Bundled Payment Model for Joint Replacements Read More »

How Trump Is Pushing Psychedelics Reform Through the Health Agencies

President Trump moved on Saturday to “reverse the crisis of serious mental illness in America” by boosting access to psychedelic drugs in clinical settings. In an executive order, he directed the federal government to rush access to treatments and reevaluate their status as controlled substances. The order directs the Food and Drug Administration to expedite

How Trump Is Pushing Psychedelics Reform Through the Health Agencies Read More »

FDA’s FY 2027 Legislative Proposals Include Game Changers for Life Science Private Equity

The U.S. Food and Drug Administration’s fiscal year 2027 budget justification includes more than 20 legislative proposals spanning drug and biologic approval pathways, supply chain oversight, advertising standards and enforcement authorities. The full package addresses topics ranging from food safety to tobacco regulation, but the subset of proposals most relevant to life science investors include

FDA’s FY 2027 Legislative Proposals Include Game Changers for Life Science Private Equity Read More »

Court Denies Shareholder’s Bid to Force UnitedHealth to Report on Acquisition Impact

A federal judge on April 15 denied a Canadian faith-based group’s request to force UnitedHealth Group to include a shareholder proposal in its upcoming proxy materials. The group, Mission Fund, had asked UnitedHealth’s board to publish a report describing the healthcare consequences of its acquisitions over the past 10 years. UnitedHealth declined to include the

Court Denies Shareholder’s Bid to Force UnitedHealth to Report on Acquisition Impact Read More »

Scroll to Top